BioSpace News Archive

Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company’s Board of Directors (the Board).

Covalon Technologies Ltd., an advanced medical technologies company, announced the results of the matters voted upon at its Fiscal 2023 Annual Meeting of Shareholders held March 6, 2024.

Evogene Ltd. today announced its financial results for the fourth quarter and full-year period ending December 31, 2023.

Bruker Corporation (Nasdaq: BRKR) is pleased to announce the successful closing of its acquisition of Chemspeed Technologies AG, a leading Swiss provider of automated laboratory R&D and QC workflow solutions.

CERo Therapeutics Holdings, Inc., today announced the publication in Clinical Cancer Research , a journal of the American Association for Cancer Research, a paper titled “ Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia.”

Arch Biopartners Inc. announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

MiNK Therapeutics, Inc. today announced that the Company will release its fourth quarter and year-end 2023 financial results before the market opens on Thursday, March 21, 2024.

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma.

Womed, the women’s health company pioneering innovative, safe and effective treatments to free women from uterine pathologies, announced that the results of the PREG2 clinical trial demonstrated Womed Leaf® is effective in the management of severe and moderate intrauterine adhesions, the primary mechanical cause for female infertility.

Reviva Pharmaceuticals Holdings, Inc. today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 36th Annual ROTH Conference, taking place March 17-19, 2024.